Arcturus Therapeutics Expands Platform with STARR™ Technology
The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution for partners. STARR™ Technology is delivered into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based therapeutic vaccine triggers rapid and immediate antigen expression within host cells and a stronger T-cell response. This combination is expected to provide longer-lasting RNA, lowering dose requirements compared to traditional RNA-based vaccines.
“We are pleased to add the STARR™ Technology to our platform,” said Pad Chivukula, Ph.D., Chief Scientific Officer of Arcturus. “Our expertise in RNA design and manufacturing combined with our LUNAR® nanoparticle delivery system may provide a unique solution to companies developing human and animal health vaccines.”
Founded in 2013 and based in
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding strategy, future operations, collaborations, the likelihood of success of the Company’s technology or potential development of any products, the status of preclinical and clinical development programs, the planned initiation of clinical trials, the expected employment of key personnel, the adequacy of the Company’s funding relative to its capital requirements and the Company’s future cash and financial position, are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading “Risk Factors” in Arcturus’ Annual Report on Form 10-K for the fiscal year ended
Arcturus Investor Contacts
Source: Arcturus Therapeutics Holdings Inc.